Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer

Autor: Anna Maria Larsson, Kristina Aaltonen, Sara Jansson, Lisa Rydén, Pär-Ola Bendahl, Carina Forsare, Charlotte Jørgensen, Mattias Bergqvist
Rok vydání: 2020
Předmět:
Adult
0301 basic medicine
Oncology
Thymidine kinase activity
medicine.medical_specialty
Prognostic factor
lcsh:Medicine
Breast Neoplasms
Kaplan-Meier Estimate
Newly diagnosed
Thymidine Kinase
Article
Tumour biomarkers
03 medical and health sciences
Breast cancer
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Biomarkers
Tumor
Overall survival
Humans
Medicine
Molecular Targeted Therapy
Neoplasm Metastasis
lcsh:Science
skin and connective tissue diseases
Thymidine kinase 1
Aged
Neoplasm Staging
Proportional Hazards Models
Aged
80 and over
Multidisciplinary
business.industry
Proportional hazards model
lcsh:R
Cancer
Middle Aged
Prognosis
medicine.disease
Metastatic breast cancer
Treatment Outcome
030104 developmental biology
030220 oncology & carcinogenesis
Female
lcsh:Q
business
Follow-Up Studies
Zdroj: Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Scientific Reports
ISSN: 2045-2322
Popis: The rapid development of new therapies in metastatic breast cancer (MBC), entails a need for improved prognostic and monitoring tools. Thymidine kinase 1 (TK1) is involved in DNA synthesis and its activity correlates to outcome in cancer patients. The aim of this study was to evaluate serum TK1 activity (sTK1) levels in MBC patients as a tool for prognostication and treatment monitoring. 142 women with MBC scheduled for 1st line systemic treatment were included in a prospective observational study. sTK1 was measured at baseline (BL) and at 1, 3 and 6 months and correlations to progression-free and overall survival (PFS, OS) evaluated. High sTK1 levels (above median) correlated to worse PFS and OS at BL, also after adjusting for other prognostic factors. sTK1 levels were significantly associated with PFS and OS measured from follow-up time points during therapy. Changes from 3 to 6 months during therapy significantly correlated to PFS and OS, whereas early changes did not. We could demonstrate sTK1 level as an independent prognostic factor in patients with newly diagnosed MBC. Changes in sTK1 levels from 3 to 6 months correlated to PFS and OS. Future studies of sTK1 are warranted to further define its clinical utility.
Databáze: OpenAIRE
Externí odkaz: